Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $1.35 Million - $1.76 Million
-18,566 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $21.7 Million - $28.9 Million
-272,138 Reduced 93.61%
18,566 $1.58 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $4.03 Million - $4.63 Million
-46,763 Reduced 13.86%
290,704 $27.9 Million
Q2 2021

Aug 16, 2021

SELL
$89.43 - $102.27 $1.78 Million - $2.04 Million
-19,907 Reduced 5.57%
337,467 $32.8 Million
Q1 2021

May 14, 2021

SELL
$87.57 - $119.4 $3.56 Million - $4.85 Million
-40,605 Reduced 10.2%
357,374 $34.8 Million
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $693,107 - $863,931
-7,975 Reduced 1.96%
397,979 $38.1 Million
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $8.03 Million - $11.3 Million
-83,510 Reduced 17.06%
405,954 $39 Million
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $601,416 - $921,384
7,068 Added 1.47%
489,464 $59.7 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $3.04 Million - $4.6 Million
-40,419 Reduced 7.73%
482,396 $41.8 Million
Q4 2019

Feb 18, 2020

SELL
$86.8 - $118.57 $691,709 - $944,884
-7,969 Reduced 1.5%
522,815 $56.2 Million
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $42.8 Million - $51.8 Million
510,286 Added 2489.44%
530,784 $47.8 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $97,379 - $123,031
1,348 Added 7.04%
20,498 $1.73 Million
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $242,585 - $320,355
3,500 Added 22.36%
19,150 $1.69 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $1.07 Million - $1.95 Million
15,650 New
15,650 $1.12 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.6B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.